+961.1%
MELI vs GSK
+80.1%
+881.1%
-69.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.5% | 0.0% | -0.5% | -0.5% |
| 7D | -4.1% | -3.5% | -0.6% | -2.8% |
| 30D | +3.8% | -3.4% | +7.2% | +5.1% |
| 3M | +17.8% | -8.1% | +26.0% | +21.1% |
| 6M | +7.4% | -11.1% | +18.6% | +11.6% |
| YTD | -5.8% | +0.7% | -6.5% | -7.4% |
| 1Y | -18.9% | +20.1% | -39.0% | -26.3% |
| 3Y | +33.3% | +46.1% | -12.8% | +6.7% |
| 5Y | +2.7% | +48.2% | -45.5% | -19.7% |
| All | +961.1% | +80.1% | +881.1% | +646.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling